Highly networked immunogen composition
AssigneesThe General Hospital Corporation, Massachusetts Eye and Ear Infirmary
InventorsBruce WALKER, Gaurav D. GAIHA, Elizabeth ROSSIN
Life of this patent
Estimating the term…
Loading patent…
AssigneesThe General Hospital Corporation, Massachusetts Eye and Ear Infirmary
InventorsBruce WALKER, Gaurav D. GAIHA, Elizabeth ROSSIN
Estimating the term…
A method of preventing or treating HIV in a subject includes selecting two or more HIV CTL epitopes from an HIV proteome that have a network score that meets a threshold value. The network score for a given epitope can be determined by generating at least one network representing protein structure, calculating a set of network parameters, combining the network parameters to determine a network score for each amino acid residue in the protein structure, generating a network score for each of a plurality of epitopes as a weighted linear combination of the amino acid residues of the epitopes, and selecting two or more epitopes according to their network score. An effective amount of a T cell immunogen composition and a pharmaceutically acceptable carrier is administered to the subject. The T cell immunogen composition includes the two or more selected HIV CTL epitopes.
A multi-epitope T cell immunogen composition comprising two or more highly networked HIV CTL epitopes, wherein the two or more highly networked HIV CTL epitopes each have a network score of at least 3.04.
A method comprising:
A method of preventing HIV infection in a subject, the method comprising:
A method comprising:
A method of preventing HIV infection in a subject, the method comprising:
A vector comprising a sequence encoding a highly networked HIV CTL epitope shown in FIG. 21 or FIG. 22, wherein the highly networked HIV CTL epitope has a network score of at least 3.06 in FIG. 21 or FIG. 22.
A vector comprising a multi-epitope T cell immunogen, wherein the vector comprises a sequence encoding two or more highly networked HIV CTL epitopes, wherein the two or more highly networked HIV CTL epitopes each have a network score from 3.04 to 9.05.
A polypeptide comprising two or more highly networked HIV CTL epitopes, wherein the two or more highly networked HIV CTL epitopes each have a network score of at least 3.04.
A method comprising engineering a human cell to comprise, on its surface, at least two or more highly networked HIV CTL epitopes each having a network score of at least 3.06 as shown in FIG. 21 or 22;
A method comprising administering a vector expressing at least two or more highly networked HIV CTL epitopes each having a network score of at least 3.06 as shown in FIG. 21 or 22;
Dependencies are inferred from the claim text.